The below snippet from the presentation seems like a load of bunkum to me , but then I have no medical qualifications , and am really only interested in OVN making decent sales which it seems incapable of doing to date .
"The first abstract examines the effect of posture on nasal resistance, showing that nasal resistance increases not only when patients lay down on their back but also when they lay on their side. Oventus’ ability to treat patients with increased nasal resistance may indicate the use of our O2Vent oral appliance therapy in patients with posture dependent obstructive sleep apnoea, in effect extending the indications for the technology. “We are pleased to be able to contribute evidence to the respiratory community that will help clinicians to better personalise treatment for patients based on the level of nasal obstruction and their sleep posture,” Dr Hart said. “Importantly, this data also reaffirms that the Oventus O2Vent device can successfully treat patients with nasal obstruction.”"
- Forums
- ASX - By Stock
- OVN
- Ann: Positive Clinical Data to be Presented at ERS Congress
Ann: Positive Clinical Data to be Presented at ERS Congress, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OVN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online